Asia-Pacific Anti-Inflammatory Therapeutics Market Expected to Reach $40.5 Billion by 2032

Asia-Pacific anti-inflammatory therapeutics market size was valued at $23.8 billion in 2022, and is projected to reach $40.5 billion by 2032, registering a CAGR of 5.4% from 2023 to 2032. Anti-inflammatory therapeutics are the medications used to reduce inflammation in the body. Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Sometimes, the body's defense system inappropriately triggers inflammation against its own cells, which results in inflammatory autoimmune diseases. Thus, therapeutics such as non-steroidal anti-inflammatory drugs such as ibuprofen or corticosteroids are used to block the enzymes that produce the anti-inflammatory effect.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Bayer AG, Novartis AG, AstraZeneca PLC, GalaxoSmithKline PLC, AbbVie Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Johnson and Johnson

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/1175

On the other hand, strong availability and emergence of new biologic drugs for the treatment of inflammatory diseases is expected to create lucrative opportunities for the market growth. For instance, Rituximab was originally approved as a cancer drug, however it has been used for the treatment of rheumatoid arthritis since 2006.

The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of drug class, indication, distribution channel, and country. On the basis of drug class, the market is segmented into biologics, NSAIDs, corticosteroids, and others. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, and inflammatory bowel disease, and others.

By distribution channel, it is divided into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Country wise, the market is analyzed across Japan, China, Australia, India, South Korea, and rest of Asia-Pacific.

On the basis of drug class, the biologics segment dominated the market in 2022, and is the fastest growing segment during the forecast period. This is attributed to strong availability of biologics drugs for the treatment of inflammatory diseases.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/1175

𝐕𝐀𝐋𝐔𝐄 𝐏𝐑𝐎𝐏𝐎𝐒𝐈𝐓𝐈𝐎𝐍𝐒 𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐓𝐎 𝐓𝐇𝐄 𝐑𝐄𝐏𝐎𝐑𝐓:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.